• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Neuronetics Inc.

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    SC 13D 1 d888051dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Neuronetics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    64131A105

    (CUSIP Number)

    Matthew Girandola

    330 Madison Avenue – Floor 33

    New York, NY 10017

    (646) 560-5490

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 10, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 64131A105    13D    Page 2 of 16 Pages

     

     

     1   

     NAMES OF REPORTING PERSONS

     

     MADRYN ASSET MANAGEMENT, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     24,237,061

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     24,237,061

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     24,237,061

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     43.6%

    14  

     TYPE OF REPORTING PERSON

     

     IA


    CUSIP NO. 64131A105    13D    Page 3 of 16 Pages

     

     

     1   

     NAMES OF REPORTING PERSONS

     

     MADRYN HEALTH PARTNERS II, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     1,335,157

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     1,335,157

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,335,157

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     2.4%

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP NO. 64131A105    13D    Page 4 of 16 Pages

     

     

     1   

     NAMES OF REPORTING PERSONS

     

     MADRYN HEALTH PARTNERS II (CAYMAN MASTER), LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     20,259,096

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     20,259,096

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,259,096

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     36.4%

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP NO. 64131A105    13D    Page 5 of 16 Pages

     

     

     1   

     NAMES OF REPORTING PERSONS

     

     MADRYN HEALTH ADVISORS II, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     21,594,253

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     21,594,253

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     21,594,253

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     38.8%

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP NO. 64131A105    13D    Page 6 of 16 Pages

     

     

     1   

     NAMES OF REPORTING PERSONS

     

     MADRYN HEALTH ADVISORS GP II, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     21,594,253

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     21,594,253

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     21,594,253

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     38.8%

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP NO. 64131A105    13D    Page 7 of 16 Pages

     

     

     1   

     NAMES OF REPORTING PERSONS

     

     MADRYN SELECT OPPORTUNITIES, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     2,642,808

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     2,642,808

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,642,808

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     4.7%

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP NO. 64131A105    13D    Page 8 of 16 Pages

     

     

     1   

     NAMES OF REPORTING PERSONS

     

     MADRYN SELECT ADVISORS, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     2,642,808

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     2,642,808

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,642,808

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     4.7%

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP NO. 64131A105    13D    Page 9 of 16 Pages

     

     

     1   

     NAMES OF REPORTING PERSONS

     

     MADRYN SELECT ADVISORS GP, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     2,642,808

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     2,642,808

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,642,808

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     4.7%

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP NO. 64131A105    13D    Page 10 of 16 Pages

     

    ITEM 1.

    SECURITY AND ISSUER.

    This Schedule 13D (this “Statement”) relates to the common stock, par value $0.01 per share (the “Common Stock”), of Neuronetics, Inc., a Delaware corporation (the “Company”). The Company’s principal executive offices are located at 3222 Phoenixville Pike, Malvern, PA, 19355.

     

    ITEM 2.

    IDENTITY AND BACKGROUND.

    (a), (f) This Statement is filed by the following persons (the “Reporting Persons”):

     

    Reporting Person

      

    State of Organization

    Madryn Asset Management, LP (“Madryn”)

      

    Delaware

    Madryn Health Partners II, LP (“MHP II”)

      

    Delaware

    Madryn Health Partners II (Cayman Master), LP (“MHP II Cayman”)

      

    Cayman Islands

    Madryn Select Opportunities, LP (“MSO” and, together with MHP II and MHP II Cayman, the “Funds”)

      

    Delaware

    Madryn Health Advisors II, LP (“MHA II LP”)

      

    Delaware

    Madryn Health Advisors GP II, LLC (“MHA GP II LLC”)

      

    Delaware

    Madryn Select Advisors, LP (“MSA LP”)

      

    Delaware

    Madryn Select Advisors GP, LLC (“MSA GP LLC” and, together with MHA II LP, MHA GP II LLC, and MSA LP the “Advisors”)

      

    Delaware

    A list of the applicable Reporting Persons’ general partners, directors, executive officers and other control persons (collectively, the “Covered Persons”) is set forth under Item 2(c). Each of the Covered Persons that is a natural person is a United States citizen and each of the Covered Persons that is an entity was organized under the laws of the state of Delaware.

    (b) The principal business address for each of the Reporting Persons and Covered Persons is 330 Madison Avenue – Floor 33, New York, NY 10017.

    (c) The principal business of each Reporting Person is set forth below:

     

    Reporting Person

      

    Principal Business

    Madryn    Investment advisor of the Funds
    Funds    Investment Fund
    Advisors    General partner of the Funds

    The principal business or occupation of each Covered Person is set forth below:

     

    Covered Person

      

    Principal Business / Occupation

    Madryn Asset Management GP, LLC    General Partner of Madryn
    Madryn Capital, LLC    Managing Member of MHA GP II LLC
    Avinash Amin    Managing Partner of Madryn
       Member of Madryn Asset Management GP, LLC
       Member of MSA GP LLC
       CEO of Madryn Capital, LLC
    John Ricciardi   

    Chief Financial Officer of Madryn

     

    Chief Operating Officer of Madryn

    Matthew Girandola    Chief Compliance Officer of Madryn


    CUSIP NO. 64131A105    13D    Page 11 of 16 Pages

     

    (d) During the last five years, none of the Reporting Persons or, to their knowledge, none of the Covered Persons, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) During the last five years, none of the Reporting Persons or, to their knowledge, none of the Covered Persons, has been a party to a civil proceeding of any judicial or administrative body of competent jurisdiction and, as a result of which they were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    ITEM 3.

    SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

    On December 10, 2024, the Company completed its previously announced transaction whereby it acquired all of the issued and outstanding common shares of Greenbrook TMS Inc. (“Greenbrook”) by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”) and in accordance with the Arrangement Agreement, dated August 11, 2024, by and between the Company and Greenbrook (the “Arrangement Agreement”). In connection with the Arrangement, Greenbrook’s shareholders, including the Funds, received 0.01021 shares of Common Stock in exchange for each of their shares of Greenbrook common stock. The Reporting Persons’ holdings in Greenbrook, consisting of an aggregate 2,373,509,547 shares of Greenbrook common stock immediately prior to the consummation of the Arrangement, was exchanged for an aggregate 24,237,061 shares of Common Stock.

    In addition, the Arrangement Agreement provides Madryn with the right to appoint two directors to the Company’s board of directors (the “Board”). Certain of the Reporting Persons may in the future enter into agreements with Avinash Amin, one of the Madryn appointees to the Board as of the date of this Statement, whereby Common Stock received by Avinash Amin as compensation for service to the Board would be assigned or transferred to Madryn or its affiliates.

    The foregoing description of the Arrangement Agreement does not purport to be complete and is qualified in its entirety by reference to the Arrangement Agreement, which is attached to this Statement as Exhibit 99.2 and incorporated by reference herein.

     

    ITEM 4.

    PURPOSE OF THE TRANSACTION.

    The information set forth in Items 3 and 6 of this Statement is hereby incorporated by reference into this Item 4.

    The Reporting Persons acquired the securities reported herein for investment purposes and intend to review their investments in the Company on a continuing basis. Depending on various factors, including but not limited to the Company’s financial position and strategic direction, price levels of the Common Stock, conditions in the securities markets, various laws and regulations applicable to the Company and companies in its industry and the Reporting Persons’ ownership in the Company, and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment in the Company as they deem appropriate, including changing their current intentions, with respect to any or all matters required to be disclosed herein. Without limiting the foregoing, and subject to any applicable limitations described in Item 6 below, the Reporting Persons may, from time to time, acquire or cause affiliates to acquire additional shares of Common Stock or other securities of the Company (including any combination or derivative thereof), dispose, or cause affiliates to dispose, of some or all of their Common Stock or other securities of the Company.


    CUSIP NO. 64131A105    13D    Page 12 of 16 Pages

     

    In addition, the Reporting Persons and their designees to the Board have had and intend to continue having discussions, from time to time, with management and the Board, and may engage with other stockholders or securityholders of the Company and other relevant parties, or take other actions concerning, the Company’s business, lines of business, operations, strategy, plans and prospects; any extraordinary corporate transactions (including, but not limited to, a merger, reorganization or liquidation); sales of a material amount of assets or divestitures; a change in the Board or management; a material change in the capitalization or dividend policies; other material changes in the Company’s business, lines of business, or corporate structure; or similar actions.

    Except as set forth herein, or as would occur upon completion of any of the matters discussed herein, the Reporting Persons have no present plans, proposals or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Although the foregoing reflects activities presently contemplated by the Reporting Persons and each of the other individuals named in Item 2 with respect to the Company, the foregoing is subject to change at any time.

     

    ITEM 5.

    INTEREST IN SECURITIES OF THE ISSUER.

    (a)-(b) The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.

    The Reporting Persons beneficially own in the aggregate 24,237,061 shares of Common Stock, which represents approximately 43.6% of the outstanding shares of Common Stock. All calculations of percentage ownership in this Schedule 13D are based on 55,652,475 shares of Common Stock outstanding, based on 30,347,504 shares of Common Stock outstanding as of November 7, 2024, as reported on the Company’s Form 10-Q for the quarter ending September 30, 2024 and filed with the U.S. Securities and Exchange Commission on November 12, 2024, increased by 25,304,971 shares of Common Stock issued in connection with the Arrangement.

    Each of the Funds directly holds the number and percentage of shares of Common Stock disclosed as beneficially owned by it in the applicable table set forth on the cover page to this Statement. Madryn, as the investment advisor for each of the Funds; MHA II LP, as the general partner for each of MHP II and MHP II Cayman; MSA LP, as the general partner for MSO; MHA GP II LLC, as the general partner for MHA II LP; and MSA GP LLC, as the general partner for MSA LP, may each be deemed to have the shared power to direct the voting and disposition of shares of Common Stock beneficially owned by the Funds and, consequently, Madryn and the Advisors may be deemed to possess indirect beneficial ownership of such shares. Madryn and the Advisors disclaim beneficial ownership of such shares for all other purposes.

    The responses of the Reporting Persons to rows 7, 8, 9, 10, 11 and 13 on the cover pages of this Statement are incorporated herein by reference.

    To the knowledge of the Reporting Persons, none of the Covered Persons owns any shares of Common Stock; provided, however, that because of each Covered Persons’ status as a director, executive officer, manager, member or partner of a Reporting Person, a Covered Person may be deemed to be the beneficial owner of the shares of Common Stock beneficially owned by such Reporting Person. Each of the Covered Persons disclaims beneficial ownership of the shares of the Common Stock reported herein and the filing of this Statement shall not be construed as an admission that any such Covered Person is the beneficial owner of any securities covered by this Statement.

    (c) Except as described herein, none of the Reporting Persons or, to their knowledge, none of the Covered Persons, has had any transactions in the Common Stock during the past 60 days.


    CUSIP NO. 64131A105    13D    Page 13 of 16 Pages

     

    (d) Except as set forth herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Common Stock.

    (e) Not applicable.

     

    ITEM 6.

    CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

    The information set forth in Item 3 of this Statement is hereby incorporated by reference into this Item 6.

    Registration Rights Agreement

    Simultaneously with the execution of the Arrangement Agreement, Neuronetics and Madryn and its affiliates party thereto (the “Madryn Parties”) entered into a Registration Rights Agreement (as amended by that certain Amendment No. 1 to the Registration Rights Agreement, dated as of November 1, 2024, the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Madryn Parties have the right to demand registration of their Consideration Shares (as defined in the Registration Rights Agreement) three-sixty-five (365) days following consummation of the Arrangement, subject to certain limitations. In addition, the Madryn Parties have certain “piggyback” rights if the Company or other holders of Common Stock undertake a registration, subject to customary cutbacks. In addition, the Madryn Parties agreed for a period of two years to vote in favor of certain Board proposals regarding the Company’s equity plan and agreed to not acquire any additional equity securities or debt securities convertible into the Company’s equity. The foregoing description of the Registration Rights Agreement does not purport to be complete and are qualified in their entirety by reference to the Form of Registration Rights Agreement and Amendment No. 1 to the Registration Rights Agreement, which are attached as Exhibits 99.3 and 99.4, respectively, to this Statement and are incorporated herein by reference.

    Joint Filing Agreement

    Pursuant to Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendments hereto, which agreement is attached hereto as Exhibit 99.1 and incorporated by reference herein.

    Except as described above and herein in this Statement, there are no other contracts, understandings or relationships (legal or otherwise) among the parties named in Item 2 hereto and between such persons and any person with respect to any of the Common Stock owned by the Funds.

     

    ITEM 7.

    MATERIAL TO BE FILED AS EXHIBITS.

     

    Exhibit 99.1    Joint Filing Agreement, dated December 17, 2024.
    Exhibit 99.2    Arrangement Agreement, dated August  11, 2024, by and between the Company and Greenbrook (incorporated by reference to Exhibit 2.1 of the Company’s Form 8-K filed on August 13, 2024).
    Exhibit 99.3    Form of Registration Rights Agreement, dated August  11, 2024 (incorporated by reference to Exhibit 10.4 of the Company’s Form 8-K filed on August 13, 2024).


    CUSIP NO. 64131A105    13D    Page 14 of 16 Pages

     

    Exhibit 99.4    Amendment No. 1 to the Registration Rights Agreement, dated November  1, 2024, by and among the Company and the Funds (incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed on November 1, 2024).


    CUSIP NO. 64131A105    13D    Page 15 of 16 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: December 17, 2024
    Madryn Asset Management, LP
    By:  

    /s/ Matthew Girandola

    Name:   Matthew Girandola
    Title:   Chief Compliance Officer
    Madryn Health Partners II, LP
    By:  

    /s/ Matthew Girandola

    Name:   Matthew Girandola
    Title:   Chief Compliance Officer
    Madryn Health Partners II (Cayman Master), LP
    By:  

    /s/ Matthew Girandola

    Name:   Matthew Girandola
    Title:   Chief Compliance Officer
    Madryn Health Advisors II, LP
    By:  

    /s/ Matthew Girandola

    Name:   Matthew Girandola
    Title:   Chief Compliance Officer
    Madryn Health Advisors GP II, LLC
    By:  

    /s/ Matthew Girandola

    Name:   Matthew Girandola
    Title:   Chief Compliance Officer
    Madryn Select Advisors, LP
    By:  

    /s/ Matthew Girandola

    Name:   Matthew Girandola
    Title:   Chief Compliance Officer
    Madryn Select Advisors GP, LLC
    By:  

    /s/ Matthew Girandola

    Name:   Matthew Girandola
    Title:   Chief Compliance Officer


    CUSIP NO. 64131A105    13D    Page 16 of 16 Pages

     

    Madryn Select Opportunities, LP
    By:  

    /s/ Matthew Girandola

    Name:   Matthew Girandola
    Title:   Chief Compliance Officer
    Get the next $STIM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Neuronetics Inc.

      SC 13D - Neuronetics, Inc. (0001227636) (Subject)

      12/17/24 9:15:11 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 1:42:23 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 11:17:47 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $STIM
    Financials

    Live finance-specific insights

    See more
    • Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

      New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, and non-drug treatment for depression MALVERN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, is proud to launch the first National TMS Therapy Awareness Day. The event will take

      5/14/25 8:31:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports First Quarter 2025 Financial and Operating Results

      MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025. First Quarter 2025 Highlights First quarter 2025 revenue of $32.0 million, an 84% increase as compared to the first quarter 2024, primarily driven by the Greenbrook acquisitionU.S. clinic revenue of $18.7 million in the quarter representing Greenbrook clinic re

      5/6/25 7:10:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 4,500 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. The RSU grants vest ratably in equal insta

      5/5/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the

      4/22/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo

      2/21/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

      MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows: Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and ope

      11/12/24 6:45:48 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 27% to 140,890 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:18 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Conley Sheryl L was granted 30,000 shares, increasing direct ownership by 16% to 214,390 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:13 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Amin Avinash was granted 30,000 shares, increasing direct ownership by 240% to 42,500 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:15 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    SEC Filings

    See more

    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 8-K filed by Neuronetics Inc.

      8-K - Neuronetics, Inc. (0001227636) (Filer)

      5/28/25 7:11:18 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Neuronetics Inc.

      10-Q - Neuronetics, Inc. (0001227636) (Filer)

      5/6/25 7:30:47 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - Neuronetics, Inc. (0001227636) (Filer)

      5/6/25 7:10:26 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics downgraded by William Blair

      William Blair downgraded Neuronetics from Outperform to Mkt Perform

      8/13/24 10:26:16 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • JMP Securities reiterated coverage on Neuronetics with a new price target

      JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

      10/14/21 8:41:45 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics downgraded by William Blair

      William Blair downgraded Neuronetics from Outperform to Mkt Perform

      10/13/21 12:25:53 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/13/24 5:02:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/6/24 5:05:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      8/30/24 5:15:02 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

      MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023. "Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," said Rob Cascella, Chairman of the Board of Neuronetics. "His depth of experience with public companies and his passion for innovative medical technologies will

      12/29/22 4:29:00 PM ET
      $BEAT
      $STIM
      Medical/Dental Instruments
      Health Care
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics